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Abstract
Human rhinoviruses (HRVs) evolve rapidly due in part to their error-prone RNA polymerase. Knowledge of the diversity of
HRV populations emerging during the course of a natural infection is essential and represents a basis for the design of
future potential vaccines and antiviral drugs. To evaluate HRV evolution in humans, nasal wash samples were collected daily
for five days from 15 immunocompetent volunteers experimentally infected with a reference stock of HRV-39. In parallel,
HeLa-OH cells were inoculated to compare HRV evolution in vitro. Nasal wash in vivo assessed by real-time PCR showed a
viral load that peaked at 48–72 h. Ultra-deep sequencing was used to compare the low-frequency mutation populations
present in the HRV-39 inoculum in two human subjects and one HeLa-OH supernatant collected 5 days post-infection. The
analysis revealed hypervariable mutation locations in VP2, VP3, VP1, 2C and 3C genes and conserved regions in VP4, 2A, 2B,
3A, 3B and 3D genes. These results were confirmed by classical sequencing of additional samples, both from inoculated
volunteers and independent cell infections, and suggest that HRV inter-host transmission is not associated with a strong
bottleneck effect. A specific analysis of the VP1 capsid gene of 15 human cases confirmed the high mutation incidence in
this capsid region, but not in the antiviral drug-binding pocket. We could also estimate a mutation frequency in vivo of
3.4610
24 mutations/nucleotides and 3.1610
24 over the entire ORF and VP1 gene, respectively. In vivo, HRV generate new
variants rapidly during the course of an acute infection due to mutations that accumulate in hot spot regions located at the
capsid level, as well as in 2C and 3C genes.
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Introduction
Human rhinoviruses (HRV) are the most frequent cause of
respiratory infection in humans [1]. These viruses belong to the
Picornaviridae, one of the oldest and most diversified human virus
family, characterized by a non-enveloped, single positive-stranded
RNA genome. Although rhinovirus replication is often restricted
to the upper respiratory tract leading to self-limited illnesses of
short duration, such as the common cold, HRV can also invade
the lower respiratory tract and lead to more serious infections
[2,3].
Similar to many other RNA viruses, the error-prone rhinoviral
polymerase can accumulate a large number of nucleotide
mutations over a very short period of time, a feature that favors
viral adaptation. The error rate of picornavirus RNA polymerases
has been estimated to range between 10
23 and 10
24 errors/
nucleotide/cycle of replication [4,5]. This variability is a driving
force for virus evolution and results in a large genetic
and phenotypic diversity illustrated by the very high number
of different HRV serotypes identified to date (http://www.
picornaviridae.com/enterovirus/enterovirus.htm). As for other
RNA viruses, the adaptive immune-mediated positive selection,
which targets the capsid region for rhinoviruses, is probably one of
the main HRV evolutionary forces at both the intra- and inter-
host levels. The in vivo selection of resistant variants during
exposure to anti-VP1 agents confirms the virus ability to rapidly
mutate the capsid protein while still conserving replicative fitness
[6–8]. The different environmental conditions of the upper and
the lower respiratory tracts could also impact on internal genes.
These observations are consistent with the full-length genome data
of all HRV serotypes that show the capsid genes VP2, VP3 and
VP1 as the least conserved [9].
Rhinovirus species and their respective serotypes have thus
emerged due to the ability to accumulate a large number of
mutations along the whole genome while preserving both
replicative capacity and transmissibility. Opportunities for these
mutational events likely occur within the context of each human
infection that is usually limited to only a few days. Therefore, it is
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evolution during the course of HRV infection in individuals,
although this does not take into account recombination events that
are also used by rhinoviruses to generate new species [10]. In
addition, it is likely that the respiratory mucosal surface is exposed
to a cloud of different variants of a quasispecies after deposition of
infectious droplets. This raises the question of whether rhinovirus
infection in humans results from the selection of a given clone
among the quasispecies (bottleneck effect) or from concomitant
infection by several different variants that are part of the
transmitted quasispecies population. Rhinovirus-positive clinical
samples collected in humans with naturally-acquired respiratory
disease are not suitable for such a study as the time elapsed since
the beginning of the infection remains unknown. For this reason,
we took advantage of samples from experimentally inoculated
adult volunteers to assess the genome evolution over a 5-day
course of infection, which is likely to represent the peak window
period of transmissibility. In parallel, we infected HeLa-OH cells
with the same HRV-39 inoculum to compare in vitro and in vivo
adaptation.
The classical Sanger sequencing method usually reliably detects
viral variants present at a frequency of at least 20% within a
heterogeneous virus population [11,12]. However, the develop-
ment of ultra-deep sequencing technologies, such as pyrophos-
phate-based sequencing (pyrosequencing) or reversible chain-
terminator extension, now allows efficient detection of viral
variants present in only 1–2% of the population [13]. In the
present investigation, we used both methods and compared results.
The aim of our study was to describe the HRV-39 genome
evolution over a 5-day period in its natural host and to analyze the
kinetics of minority mutations (i.e. low-frequency mutations
present between 2–50% within the viral population) in vivo and
in vitro following inoculation with a quasispecies cloud of viral
variants. This allowed us to point out regions along the HRV-39
open reading frame (ORF) that were enriched for mutations or
conserved, and to determine whether the HRV genome evolution
after 5 days of infection shares similarities with the general long-
term HRV evolution history. Collectively, these results should
contribute to evaluate the ability of HRV to generate new variants,
as well as their ability to escape antivirals and vaccines.
Results
Viral load and HRV-39 kinetics infection in inoculated
subjects
Nineteen human volunteers were infected with a standardized
quantified inoculum (,1000 50% tissue culture infective dose/
mL) of an HRV-39 viral stock. We then collected nasal wash (NW)
samples from days 0 to 5 to assess the kinetics of the HRV-39 viral
load by real-time PCR. Four of 19 subjects were found to be
rhinovirus RNA- positive the day prior to inoculation, either from
a recent or ongoing infection, and were excluded from this
analysis. As expected, real-time PCR performed on NW samples
were positive for all but one subject at day 5. Although differences
in HRV-39 viral loads were observed between individuals, viral
titers peaked consistently between days 2 and 3 before starting to
decline (Fig. 1). These results confirm previous observations with
HRV-16 inoculation that relate a similar peak 48 h post-infection
correlating with the peak of symptom scores [14].
Mutation analysis along the whole ORF by ultra-deep
and classical sequencing methods
Generation of new mutations in the course of infection
and adaptation to a specific host. The dynamics of HRV-39
minority mutation evolution were analyzed by ultra-deep
sequencing of three samples collected at day 5 post-infection
(two clinical, one in vitro) by comparing the entire ORF of the
initial HRV-39 inoculum with the sequence obtained in two
human subjects (P1073 and P1077) and in HeLa-OH cells (HeLa-
A). To exclude mutation introductions linked to RT or DNA
polymerase errors, each RNA extracted from human NW or
HeLa-OH cell samples was reverse transcribed in duplicate and
amplified by PCR in quadruplicate. The presence of single
nucleotide mutations identified by the ultra-deep sequencing
approach was considered only if statistically reproducible in each
of our replicates (see Materials and Methods).
A Venn diagram provides an overview of the repartition of
minority mutations in the four different viral populations analysed
and shows individual overlaps (Fig. 2A). The total number of
minority mutations detected in the four viral populations was 45.
The number of minority mutations detected in the original
inoculum was 32, thus revealing that 13 additional minority
mutations appeared in the three populations studied after 5 days of
viral replication. Most minority mutations present in the inoculum
were detected in at least one of the two subjects studied (25/32)
with 14 kept within the two viral populations (Fig. 2A, B), thus
suggesting that most initial variants had passed in these infected
volunteers. Similar results were observed in HeLa-OH cells (21/32
minority mutations conserved, Fig. 2A, B). Viral populations
present in NW samples of subjects P1073 and P1077 and the cell
supernatant were composed of 24, 26 and 26 minority mutations,
respectively, with 21%, 23% and 19% representing new minority
mutations having emerged during the 5-day infection period.
During the course of infection, four minority mutations present
in the inoculum were counter-selected (one in VP1, one in 2C
NTPase A site [15], two in 3D) and two, five and three appeared
specifically in patients P1073 (one in VP1 NIm-IB domain [16],
one in 2C NTPase A site), P1077 (one in VP2, one in 2C and three
in 3D) and in HeLa-A (two in 2C NTPase A site, one in 2C zinc
finger motif [17]), respectively, and were present at similar
frequencies compared to all minority mutations. Finally, two
minority mutations were present both in HeLa-A and P1073 (one
in VP1, one in 3C) and one in both P1073 and P1077 (located in
2C). Overall, we did not observe a significant difference in terms of
the number of new mutations appearing in human and HeLa-OH
cells.
Distribution of mutations along the ORF. We estimated
the initial and final densities of minority mutations along the ORF
with kernel functions using the ultra-deep sequencing data and
were able to identify regions with a higher density of mutations
(Fig. 3). The distribution and pattern of these spots along the ORF
were similar between the inoculum and the viral populations
analyzed after 5 days of replication in humans or cells. Most
minority mutations are located within VP2, the second half of
VP1, and the 2C genes (see filled and dashed curves, Fig. 3A, B,
C). Interestingly, no minority mutations were detected within the
VP1 drug-binding pocket [6], thus suggesting a relative stability of
this structure, at least in the absence of specific pressure. This
analysis also identified the presence of regions that were highly
conserved: in VP4, from the start of 2A to the end of 2B; in 3A, 3B
genes; and finally in 3D (the polymerase gene).
Comparison of the P1073, P1077 or HeLa-A sample sequences
with that of the initial HRV-39 inoculum was then performed to
determine both the presence of the new majority species (defined
as a frequency change of over 50%) and the amplitude of all
mutation frequency changes in the population after 5 days’
infection (Fig. 3A, B, C, colored bars). This analysis shows the
presence of three majority nucleotide changes along P1073 ORF,
HRV Evolution in Human
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number of mutation (minority and majority mutations) frequency
changes were similar between P1073, P1077 and HeLa-A and
mainly located within regions previously identified as being
enriched of mutations. Interestingly, all 14 minority mutations
present in the four viral populations in Fig. 2 are mainly located
within these highly variable regions (VP1 [4/14], VP2 [2/14], 2C
[5/14], VP3 [2/14] or 3C [1/14]), but not in regions depleted of
mutations identified above.
Majority species after five days of infection. We
performed also Sanger sequencing in parallel on the entire ORF
of the specimens analyzed above, as well on NW samples from
three additional patients (P1062, P1120 and P1074) and cell
supernatants from four additional experiments (HeLa-B to E).
Again, consensus sequences after 5 days of viral replication were
compared to the inoculum sequence (Fig. 4A). This analysis
confirmed the ultra-deep sequencing as all the nucleotide changes
identified previously for P1073, P1077 and HeLa-A samples are
strictly those identified by the Sanger sequencing. A total number
of four non-synonymous (two non-conservative, present both in
P1073 at the full-length positions 2647 in VP1 and 4831 in 2C)
and seven synonymous mutations were found in samples from
human subjects. Similar to the ultra-deep analysis, most mutations
are located within the viral capsid genes VP1 (3/11), VP2 (2/11)
and VP3 (3/11), while VP4 (0/11), 2A (0/11), 2B (0/11), 3A (0/
11), 3B (0/11) and 3D (1/11) regions were confirmed to represent
relatively conserved regions with few or no mutations identified.
Fourteen non-synonymous (six non-conservative: one present in
HeLa-D at the HRV-39 full-length position 2464 in VP1, and one
present in the five HeLa-OH experiments at position 4831 in 2C)
and 13 synonymous mutations were found in cells. Again, most
mutations (15/27) are located within the viral capsid genes VP2,
VP3 and VP1, while no mutations were present in VP4, 2A, 3A,
3B, and only one in 2B and 3D. None of the mutations observed
both in vivo and in vitro is located in HRV domains with known
functions [15–21].
Finally, taking into account the number of patients or cells
analysed and the length of the ORF, we estimate that the
occurrence of major mutations after 5 days of HRV-39 infection in
human subjects is of 3.4610
24 mutations/nucleotides (total of 11
mutations/[5 subjects 66443 nucleotides analysed]) versus
8.4610
24 in cells (total of 27 mutations/[5 HeLa-OH assays 6
6443 nucleotides analyzed]).
In vivo and in vitro VP1 sequence analysis
The capsid protein VP1 is responsible for receptor binding and
is also a target for certain antivirals. In addition, this protein is the
most exposed viral protein at the capsid surface and the main
inducer of neutralizing antibody. As this gene was identified as a
region with a high frequency of mutations in our previous analysis,
we assessed by classical sequencing the frequency of point
mutations in natural HRV hosts by comparing the VP1 consensus
sequences at day 5 post-HRV-39 infection versus the initial
sequence present in the HRV-39 inoculum for all 15 subjects.
Figure 1. Kinetics of HRV-39 infection in inoculated patients. The course of infection is shown from days 0 to 5 for each patient (P). The
relative HRV RNA values are expressed as 1/CT and converted into % with 100% being arbitrarily set for each patient at day 1. The mean value is
represented by the black line. Subjects analyzed further by ultra-deep sequencing are marked with an asterisk.
doi:10.1371/journal.pone.0010588.g001
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mutation introduced by RT-PCR or sequencing. The sequence
comparison revealed the occurrence of a single point mutation in
three of the 15 subjects, one synonymous at HRV-39 full-length
position 2711 for two subjects (P1105 and P1073) and one non-
synonymous/non-conservative at position 3162 for one subject
(P1062) (Table 1). In addition, a mixed population was found at
position 2647. Thus, we can estimate that the VP1 mutation rate
Figure 2. Representation of all specific or common minority mutations to be found in the same loci for the four samples analysed
by ultra-deep sequencing. (A) Venn plot showing the minority mutations present initially in the HRV-39 inoculum and those present in HeLa-A,
P1073 and P1077 after 5 days of infection. (B) Minority mutations present in the initial inoculum and in subjects P1073 and P1077 after 5 days of viral
replication in the nasopharyngeal epithelium are represented by black and blue at their respective positions along the HRV-39 ORF. Blue bars
represent the 14 minority mutations present in the Venn plot in the four viral populations.
doi:10.1371/journal.pone.0010588.g002
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approximately 3.1610
24 mutations/nucleotides (total of 4 muta-
tions/[15 subjects 6854 nucleotides analyzed]).
In comparison, eight VP1 mutations were identified in the five
HeLa-OH cell experiments after 5 days of infection. The
synonymous mutation at position 2711, previously observed in
vivo for two subjects, was present in all HeLa-OH cells. Each of
the three remaining non- synonymous mutations (the one at HRV-
39 full-length position 2400 representing a mixed population) was
present in only one of the five cell experiments. Based on these
data, we estimate that the occurrence of VP1 mutation after 5 days
of HeLa-OH cell infection with HRV-39 is of 1.9610
23 muta-
tions/nucleotides (total of 8 mutations/[5 HeLa-OH assays 6854
nucleotides analyzed]). Regarding the complete ORF, VP1
mutation frequency is higher in vitro under our conditions than
in vivo in experimentally infected individuals with a reference
Figure 3. Change in mutation frequencies (minority and majority mutations, colored bars) and minority mutation densities
(curves). Colored bars represent the difference in proportions of each nucleotide between the inoculum and the final (5 days’ post-infection) sample
in HeLa (A), subjects P1073 (B) and P1077 (C). As each gain in proportion by one nucleotide must be a loss by another, the changes sum to zero.
Crosses indicate non-synonymous mutations. Curves indicate minority mutation densities (estimated by a Gaussian kernel function), including
mutations whose nucleotide proportions did not change between the inoculum and the final sample.
doi:10.1371/journal.pone.0010588.g003
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vitro is located in neutralizing immunogens or within the VP1
drug-binding pocket. No mutations were found in the cis-acting
replication element, which is located in the 2A gene for human
rhinovirus A [22].
Discussion
The study of HRV genome evolution is limited by the lack of
animal models and the short duration of most human infections.
To bypass this limitation, we analyzed the HRV genome evolution
in experimentally infected human volunteers and compared our
results with those obtained in an in vitro culture model. Our
analysis based on 15 HRV-39 inoculated subjects first confirms
that the peak viral load is reached at days 2 or 3 post-infection, as
shown previously in HRV-39- or HRV-16-inoculated subjects.
This correlates also with the kinetic of common cold symptoms
[14,23,24]. Relatively high levels of viral RNA are still found 5
days’ post-infection, although substantial inter-individual varia-
tions were observed and suggest that factors including the host
innate immune responses (all individuals presented a serum
neutralizing antibody titre of 1:4 or less against the reference
HRV-39 strain suggesting a minor effect of the adaptive-immune
responses) could modulate viral replication. Most importantly, our
analysis was conducted during a period of time that corresponds to
the main period of transmissibility [25] and during a high rate of
replication cycles.
By using ultra-deep sequencing technology, we were able to
pinpoint HRV evolution at the level of a quasispecies population
both in vivo and in vitro. Our data illustrate the ability of
Figure 4. Comparison of ORF consensus sequences in HeLa-OH and human volunteers. (A) Five HeLa-OH (A to E) and samples from five
human volunteers (P1062, P1120, P1073, P1074 and P1077) collected 5 days’ post-infection were analysed by classical sequencing method. All
mutants present after 5 days of infection, as well as those already present as minority mutations in the initial HRV-39 inoculum, are shown at their
respective genome position. Synonymous, non-synonymous and non-conservative mutations are represented by black, and blue and red symbols,
respectively. (B) The conservation plot was calculated based on an alignment of 99 rhinovirus serotypes as previously published [9]. The average
sequence identity for the ORF was 69.9% (blue dashed line).
doi:10.1371/journal.pone.0010588.g004
Table 1. Analysis of VP1 consensus sequences.
Mutations Nucleotide HeLa-OH Subjects Amino Acid
(FL position) in Inoculum A B C D E P1062 P1073 P1105
2400 C C:T (50:50) VP124 HRY
2464 T C VP145 IRT
2647 A A:T (50:50) VP1106 QRL
2711 A T T T T T T T VP1127 (P)
2821 G C VP1164 GRA
3162 T C VP1278 SRP
Majority mutations present in VP1 after 5 days of HRV-39 infection in five independent HeLa-OH cell experiments (A to E) and in 15 inoculated human volunteers are
represented. Non-synonymous mutations are in bold and non-conservative in bold and italic. The nucleotide and amino acid positions are indicated relative to the HRV-
39 reference sequence (Genbank accession # AY751783), complete genome and VP1 protein, respectively.
doi:10.1371/journal.pone.0010588.t001
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post-infection. This represents a minimal estimate of replicating
minority variants since mutations present at frequencies lower
than the ultra-deep sequencing limit of detection are not
represented here.
The transmission of viral populations between hosts and the
subsequent mucosal infection could lead to a bottleneck effect that
selects for a limited number of variants. Indeed, for other RNA
viruses, such as HIV, infection might result from the selection of
very few clones and it seems likely that as few as 1 to 5 viral
particles could initiate an infection [26]. This effect was not
observed for HRV since our ultra-deep sequencing analysis shows
that most minority mutations present in the initial HRV-39
inoculum were transmitted and replicated in both human subjects
and HeLa-OH cells (Fig. 2). Thus, based on our experimental
conditions, it appears that HRV inter-host transmission is not
associated with a strong bottleneck effect. We observed simulta-
neous co-infection with several minority variants together with the
dominant population.
To the best of our knowledge, our study allowed to define for
the first time a virus mutational map on the entire ORF in vivo.
Both classical and ultra-deep sequencing methods revealed the
presence of mutation hot spots along the entire coding sequence in
the viral capsid genes VP1, VP2 and VP3, whereas cold spots were
found in VP4, 2A, 2B, 3A, 3B and 3D. Interestingly, this is
consistent with previous published data that compared the RNA
genome sequence of prototype HRVs serotypes (Fig. 4B) [9]. A
previous analysis based on the study of 35 HRV full-length
sequences has already demonstrated that the HRV genome was
under purifying selective pressure with islands of diversifying
pressures located in VP1, VP2, VP3, 3C and 3D genes [27]. Our
results obtained after 5 days of viral replication in human subjects
and HeLa-OH cells confirm that VP1, VP2, VP3 and 3C, but also
2C genes, appeared to be under a diversifying pressure compared
to others parts of the ORF (Fig. 2, 3, 4). A similar evolutionary
pattern was observed in experimentally infected humans as well as
in vitro, thus suggesting an evolutionary pattern common to the
HRV species. Whether the presence of these mutation hot spots
are linked to host immune pressure and/or to intrinsic replication
constraints of the virus remains to be elucidated. However,
knowledge of hot and cold spots may contribute to the
identification of stable targets for new antiviral and vaccine
therapies. This also contributes to our understanding of the
diversity of one of the most frequent agents infecting humans.
When analyzing the occurrence of mutations in VP1 gene in
both inoculated human subjects and HeLa-OH cells, we found a
lower mutation frequency in vivo in humans (3.1610
24) than in
vitro in HeLa-OH cells (1.9610
23). The mutation frequency
estimations based on the ORF sequences strengthened these
results (3.4610
24 and 8.4610
24 in humans and HeLa-OH cells,
respectively) and are consistent with published data that estimate
an error rate of picornavirus RNA polymerases ranging between
10
23 and 10
24 errors/nucleotide/cycle of replication [4,5]. HRV
is one of the most frequent viral agents in humans with more than
100 serotypes co-circulating that have emerged through repeated
infections of short duration. The mutation frequency observed in
our study is rather limited and at the lower end of what might have
been expected, thus suggesting that HRV serotypes (at least for
HRV-39) have already evolved over a prolonged period of time.
Furthermore, in the absence of any knowledge of the number of
replication cycles, we should be careful to draw any definitive
conclusion between in vitro and in vivo conditions. Still, these
differences could be explained by the fact that the HRV-39
inoculum might be more human-adapted as it was previously
cultured only twice in WI-38 diploid fibroblasts. Second, human
volunteers and HeLa-OH cells were not inoculated with the same
TCID50/mL (10
3 and 10
2 TCID50/mL, respectively) as HeLa-
OH cells did not sustain 5 days of infection as with the one used to
infect human subjects. Third, the relative percentage of infected
cells is likely to be higher in vitro.
The Sanger sequencing analysis performed on the entire ORF
of 5 HeLa-OH and 5 NW samples showed a similar ratio of
synonymous and non-synonymous mutations mainly located in
hot spot regions identified by the relative mutation density
analysis. Both in HeLa-OH and in human subjects, half of the
non-synonymous mutations were non-conservative and were all
located in VP1 and 2C genes. Interestingly, the change observed
at position 2711 seems to have a beneficial effect at the genome
level (synonymous) in HeLa-OH cells since this mutation emerged
in all five independent experiments in HeLa-OH. This was
observed only twice among the 15 human cases. Only functional
studies could determine whether this specific mutation could
provide a phenotypic advantage in vitro. Our data demonstrate
the intrinsic ability for an already human-adapted HRV to
generate new mutations in the VP1 region during the course of an
acute infection in vivo. This latter point is of importance as VP1
contains sites for both antigen recognition and antiviral drug
targets, such as pleconaril [6,7]. Interestingly, after 5 days of
infection, no mutations arose within the VP1 drug-binding pocket
both in vivo and in vitro, but in the absence of any drug pressure.
Importantly, we did not find any mutations by both ultra-deep
or classical Sanger sequencing methods within any previously
known HRV functional domains (that are expected to tolerate a
minimal number of mutations) and these were largely located in
viral structural genes. This suggests that ultra-deep sequencing
might represent a powerful tool to identify previously unknown
functional domains that should be evidenced as cold spot regions.
In addition, this approach is extremely useful for the study of any
viral populations and quasispecies that cannot be grown in cells.
Finally, this approach performed on different HRV serotypes
could bring information on their respective evolutionary status as
viruses having frequently circulated in humans should be more
adapted and thus less susceptible to variations during the course of
a human infection.
In summary, we took advantage of samples from experimentally
inoculated volunteers to characterize HRV genome evolution over
a 5-day course of infection, which represents the maximal window
period of transmissibility. Ultra-deep sequencing analysis on
minority mutation frequency and distribution allowed to identify
hot spot and cold spot regions along HRV-39 ORF present both
in vivo and in vitro. Our experiments suggest that HRV inter-host
transmission is not associated with a strong bottleneck effect.
Continued efforts to improve our understanding of HRV
evolution in its natural host are essential as they represent the
basis for the design of future potential vaccines and antiviral drugs.
Materials and Methods
Ethics statement
Written informed consent was obtained from all individuals
prior to study participation. The study was approved by the
Institutional Review Boards (IRB) of the University of Virginia,
Charlottesville, Virginia, and the Medical University of South
Caroline, Charleston, South Carolina.
Study participants
Subjects were enrolled in a clinical study after informed consent
and following review of the IRB at the University of Virginia,
HRV Evolution in Human
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antiviral compound and only placebo-treated subjects were
considered for the present study. Individuals were required to be
previously healthy, between 18 to 65 years of age, and to present a
serum neutralizing antibody titre of 1:4 or less against the
reference HRV-39 strain. Exclusion criteria were a history of
allergic disease or nonallergic rhinitis, abnormal nasal anatomy or
mucosa, or a clinically diagnosed respiratory tract infection in the
previous two weeks. Pregnant or lactating women or women not
taking medically approved birth control were also excluded.
HRV-39 inoculum
The HRV-39 strain, commonly used for human inoculation
studies, was initially recovered from a volunteer and cultured twice
in WI-38 diploid fibroblast cultures according to standard
recommendations to obtain a sufficient stock. The inoculum was
tested to be safe for human in vivo usage [28].
We analyzed nasopharyngeal specimens of 19 consecutive
subjects inoculated with viral stocks of ,1000 50% tissue culture
infective dose (TCID50)/mL administered as drops in two inocula
of 250 ml per nostril given approximately 15 minutes apart while
subjects were supine. NW samples were collected daily for 5 days
by instillation of 5 mL of 0.9% saline into each nostril and stored
at 280uC for subsequent assay.
Quantitative real-time RT-PCR
HRV-39 RNA was TRIzol-extracted (Invitrogen, Carlsbad,
CA, USA) from 190 ml of NW samples collected daily or HeLa-
OH infected supernatant according to the manufacturer’s
instructions. As an internal control, 10 ml of standardized Canine
Distemper Virus (CDV) of known concentration were added to
each sample before extraction. Extracted RNA was used as a
template for the synthesis of cDNA with random hexamers
(Roche, Indianapolis, IN, USA) or oligo-dT primers (Roche) at
42uC using the reverse transcriptase (RT) SuperScript II
(Invitrogen) according to manufacturer’s instructions. cDNA was
then amplified and detected in a TaqMan real-time PCR reaction
using a validated human picornavirus combination of primers and
probes named ‘‘Panenterhino’’ [29] and the CDV assay (primers:
CDV-fwd: 59-gctacccaagaaaccgtcattg-39, CDV-rev: 59-gcatgg-
cagggacgagtt-39, probe: CDV-probe: 59-VIC-cgttcagggagtccag-
gactacgtcaac-TAMRA-39), respectively, under the following cy-
cling conditions: 50uC for 2 min; 95uC for 10 min; 55 cycles of
95uC for 15 s and 60uC for 1 min in a 7500 Applied Biosystems
thermocycler. Results were analyzed using the SDS version 1.4
program (Applied Biosystems, Foster City, CA, USA). Quantita-
tive assays were run using a 10-fold dilution series of a titrated
HRV-39 stock (ATCC) that was used as a reference quantitative
curve for each run. In addition, we obtained Ct values for the
CDV assay in each run to control for intra- and inter-assay
variability.
Cell culture and infection
HeLa-OH cells were grown in Eagle’s Minimum Essential
Medium (EMEM; Lonza, Wokingham, UK) supplemented with
2 mM L-glutamine, 1 mg/mL amphotericin, 100 mg/mL genta-
micin, 20 mg/mL vancomycin, and 10% fetal calf serum (FCS) at
37uC in a 5% CO2-containing atmosphere. The original HRV-39
inoculum (10
6 TCID50/mL) used to inoculate the human subjects
was diluted 10
4-fold in 1 mL (10
2 TCID50/mL) of McCoy’s 5A
Medium–2% FCS to infect, with this 1 mL, 80% confluent HeLa-
OH in 33 mm wells for 2 h at 33uC. Cells were washed twice with
PBS (Ca
2+ and Mg
2+ free). Finally, 1 mL of fresh McCoy’s 5A
Medium–2% FCS was added in each well and cells were
incubated at 33uC. Supernatants were recovered and extracted 5
days’ post-infection for real-time PCR analysis and sequencing.
This procedure was repeated in five independent experiments.
VP1 gene and full-length genome amplification by PCR
VP1 amplicon was obtained by amplification of two overlapping
PCR fragments (primers VP12195/VP12860 and VP12626/VP13325,
Figure S1). The HRV-39 ORF sequence (nucleotide 615 to 7058)
was obtained by amplification of eight overlapping PCR products
with primers HRV39-1 to 8 forward/reverse (Figure S1). For
ultra-deep sequencing, RT was performed in duplicate and each
PCR in quadruplicate to discard any mutations introduced by
polymerase errors. We used Pfx50 DNA polymerase for PCRs
according to the manufacturer’s instructions. All amplicons were
purified with the microcon columns (Millipore, Zug, Switzerland)
before sequencing. PCR quadruplicates originating from the same
RT reaction were pooled at equimolar concentrations and used for
ultra-deep sequencing.
Both VP1 and ORF classical sequencing were performed in
duplicate directly on PCR products with the same primers used for
each individual PCR. Sequencing was performed with ABI Prism
3130XL DNA Sequencer (Applied Biosystems). Chromatograms
were imported for proofreading with the vector NTI Advance 10
program (Invitrogen). Overlapping fragments were assembled with
the contigExpress module of the vector NTI Advance 10.
Ultra-deep sequencing analysis
Samples. Libraries were prepared according to the
manufacturer’s protocol (Illumina, Inc., San Diego, USA) using
bar-coded adapters designed by Fasteris. Each library consists of
eight PCR products pooled at equimolar concentration and
fragmented by nebulization. After end repair to generate blunt
ends and the addition of one A at the 3’ends, fragments were
ligated with a modified genomic adapter containing a four-base
bar-code at its 3’end and purified on agarose gel to recover
fragments of approximately 300 bp. PCR amplification was
performed for 15 cycles using the Phusion polymerase. Libraries
were purified and quality controlled by cloning a 1 ml aliquot into
a pCR4Blunt-TOPO plasmid (Invitrogen) and capillary
sequencing of eight clones to verify correct constructs and
inserts. We quantified the libraries using BioAnalyzer (Agilent,
USA) and Q-bit (Invitrogen) and diluted to 10 nM.
Genome analyzer run. Libraries were pooled and
sequenced on an Illumina Genome Analyzer GAII single-read
channel for 76 cycles using a version 3 sequencing kit. We
performed base-calling using Illumina GAPipeline-1.3.2, which
produced over four million pass filter reads or 329 Mb.
Bioinformatics data analyses. An average of 3.5610
5
HRV-39 mapped reads was obtained for each sample analyzed
with a mean coverage of 4100 readings per nucleotide. Short reads
were first mapped with MAQ software version 0.7.1 accepting a
maximum of two mismatches within the first 24 bases on the
HRV-39 reference sequence (Genbank accession AY751783).
Reads mapping on repeated regions were attributed randomly to
one of the possible locations. The MAQ consensus sequences,
including SNP detection, were generated for all regions with a
minimum coverage of three bases. We conducted a statistical
analysis of the counts of the number of mapped A/C/G/T to
extract potential SNP positions for each position on the reference
sequence. Counts are used to determine the 95% confidence
interval of the probability of observing A/C/G/T at the position
while assuming the probabilities to follow a beta distribution.
When the confidence interval of two of the bases probability is
above a 5% threshold, the position is considered as a statistically
HRV Evolution in Human
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version 0.7.31 and the resulting contigs were compared using
dnadiff (MUMmer version 3.20) with the MAQ consensus
sequence to validate minority mutations and discover insertions-
deletions (indels). All reads were also mapped with DNASTAR
NGen on the HRV-39 reference sequence and on capillary
sequences obtained in our laboratories. We performed
visualization and minority mutation detection using DNASTAR
SeqMan version 8.0.
Venn diagram. Significant mutations showing common loci
in the four different samples and their individual overlaps were
visualized in a Venn diagram using the statistical package R [30]
and the R script overLapper.R (http://faculty.ucr.edu/,tgirke/
Documents/R_BioCond/My_R_Scripts/overLapper.R; accessed
February 1, 2010).
Mutation analysis along the whole HRV-39 ORF. The
variation in relative frequency of a given base at a specified
position is expressed as ‘‘final relative frequency–initial relative
frequency’’ for that base at that position. The relative frequency of
a given base at a given position is expressed as the base’s count
divided by the count of bases at that position. The algebraic sum of
all variations at a given position is always zero. Density of
mutations, including those which did not exhibit change in base
frequencies, was represented with a Gaussian kernel density
function using a smoothing band width of 0.1 kernel standard
deviation. The curves are shown at the same scale and normalized
so that a value of 1 is the highest density found over all genomes.
Graphs, including kernel estimates, were produced with the R
statistical package.
HRV ORF conservation plot. We conducted an RNA
sequence identify plot for the ORF of an alignment covering all
known human rhinoviruses (pmid:19213880). The plot was
drafted using R [30] and the packages bio3d [31] and zoo [32].
All-against-all identities were assigned for each column and
average; sliding windows of 30 nucleotides with a step size of
one nucleotide were used to compute a moving mean sequence
identity percentage that was then plotted.
Supporting Information
Figure S1 Primers used to amplify and sequence the human
rhinovirus 39 capsid protein VP1 and the entire open reading
frame.
Found at: doi:10.1371/journal.pone.0010588.s001 (8.94 MB TIF)
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